NEW YORK, Dec 12 (Reuters) - A big stock buyback or an increased dividend could lift Pfizer Inc PFE.N shares to $25 over the next year, and the retirement of former CEO Jeff Kindler also gives Pfizer an opportunity to shed assets, Barron's said in its Dec 13 edition.
Pfizer, now led by Ian Read, may also reduce its huge $9 billion research-and-development budget, the investment weekly said.
Pfizer’s higher-value businesses, like animal health and infant nutritionals, could be valued at around $27 billion if they were sold or split off, Barron’s said.
Clues to the company’s strategy could come in the next few days as Pfizer names its board chairman. Investors would cheer if board member Jim Kilts, who led Nabisco and Gillette, gets the job, Barron’s said. Investors would be less pleased if former Pfizer CEO William Steere becomes chairman, according to the investment weekly. (Reporting by Nick Zieminski; Editing by Jan Paschal)
Our Standards: The Thomson Reuters Trust Principles.